Carbamazepine-10,11-epoxide formation pathway (CBZ-E pathway)

The Carbamazepine-10,11-epoxide formation pathway is the principal metabolic route for the antiepileptic drug carbamazepine in the human liver (NIH, 2023). This biotransformation is primarily mediated by the cytochrome P450 enzyme CYP3A4, with additional contributions from CYP2C8 and CYP3A5 (ResearchGate, 2006; NIH, 1994). The process converts carbamazepine into its stable, pharmacologically active metabolite, carbamazepine-10,11-epoxide (CBZ-E), which contributes significantly to the drug's therapeutic efficacy (Wikipedia, 2025). CBZ-E exerts anticonvulsant and analgesic effects by inhibiting voltage-gated sodium channels, similar to the parent drug (NIH, 1998). However, the accumulation of this epoxide is also linked to neurotoxic side effects and potential teratogenicity during pregnancy (Mayo Clinic, 2025). The pathway concludes with the detoxification of CBZ-E by microsomal epoxide hydrolase (EPHX1) into an inactive trans-diol metabolite (NIH, 2013). Clinical management often requires monitoring this pathway due to significant drug-drug interactions; for example, inhibitors of EPHX1 like valproic acid can cause toxic elevations of CBZ-E levels (NIH, 1998).

Other names

Carbamazepine epoxidationCBZ-E metabolic pathwayCYP3A4-mediated carbamazepine metabolism

The pathway produces carbamazepine-10,11-epoxide, which acts as a voltage-gated sodium channel inhibitor to stabilize hyperexcited neuronal membranes.